Upper Gastrointestinal Bleeding

Gastroenterology
1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
Omeprazole sodium bicarbonate immediate release PWD/FSPhase 31 trial
Active Trials
NCT00045799CompletedEst. May 2003
Mission Therapeutics
Mission TherapeuticsUK - Cambridge
1 program
RISK STRATIFICATION USING AIMS65 SCORE AND RDWN/A1 trial
Active Trials
NCT04825977Completed348Est. Oct 2020
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Study of Incidence of Drug-induced Upper Gastrointestinal BleedingN/A1 trial
Active Trials
NCT01155401Completed300Est. Jun 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch HealthOmeprazole sodium bicarbonate immediate release PWD/FS
Mission TherapeuticsRISK STRATIFICATION USING AIMS65 SCORE AND RDW
AstraZenecaStudy of Incidence of Drug-induced Upper Gastrointestinal Bleeding

Clinical Trials (3)

Total enrollment: 648 patients across 3 trials

NCT00045799Bausch HealthOmeprazole sodium bicarbonate immediate release PWD/FS

Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill

Start: May 2002Est. completion: May 2003
Phase 3Completed
NCT04825977Mission TherapeuticsRISK STRATIFICATION USING AIMS65 SCORE AND RDW

Risk Stratification of Patients Presenting With Upper Gastrointestinal Bleeding to the Emergency Department Using AIMS65 Score and Red Cell Distribution Width

Start: Aug 2018Est. completion: Oct 2020348 patients
N/ACompleted
NCT01155401AstraZenecaStudy of Incidence of Drug-induced Upper Gastrointestinal Bleeding

Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding

Start: Jun 2010Est. completion: Jun 2011300 patients
N/ACompleted

Related Jobs in Gastroenterology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space